Incyte Pharma (INCY) - Gross Profit Margin

Official company branding of Incyte Corp (INCY)

Incyte Corporation (INCY) offers vital monopoly solutions for the therapy of complex hematological pathologies. Gross margin stability on the GURU.Markets chart demonstrates current dynamics, where the latest value is recorded as 91.50. High profitability is based on Jakafi patents, while business resilience is ensured by the conservatism of medical protocols and colossal costs associated with developing new formulas.

INCY (Incyte Pharma) Return on Gross Profit history from 07/04/2022 to 11/20/2026

Financial and market metric breakdowns for Incyte Corp (INCY)

- market price and analyst price targets:
Basic company analysis:Incyte (INCY)
Manufactured products of Incyte

The selection of high-quality issuers is based on the stability of key efficiency multiples. Gross margin measures the profit share after deducting direct production costs, reflecting the business's fundamental ability to generate cash flow. For Incyte Corporation (INCY), portfolio diversification between dermatology and oncology optimizes cost of goods sold and mitigates patent risks. Analyzing the gross margin trend allows an investor to assess the sustainability of the company's operating profitability.